Working… Menu

Dose-Finding Study of Cabozantinib (XL184) in Japanese Subjects With Advanced Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01553656
Recruitment Status : Completed
First Posted : March 14, 2012
Last Update Posted : August 20, 2015
Information provided by (Responsible Party):

Brief Summary:
The purpose of this study is to evaluate the safety profile, tolerability, pharmacokinetics (PK), pharmacodynamics, pharmacogenomic (PGX) and preliminary efficacy following daily oral doses of cabozantinib (XL184) in Japanese patients with advanced or metastatic solid tumors. Also, the effect of XL184 in the treatment of non-small cell lung cancer (NSCLC) patients with various activating mutations will be evaluated at the recommended Phase 2 dose.

Condition or disease Intervention/treatment Phase
Solid Tumors Cancer NSCLC Drug: cabozantinib capsules Drug: cabozantinib tablets Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 85 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase 1 Multiple Ascending Dose Study of XL184 Monotherapy in Japanese Subjects With Advanced or Metastatic Solid Tumors
Study Start Date : February 2011
Actual Primary Completion Date : May 2015
Actual Study Completion Date : July 2015

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Cabozantinib capsules and tablets
Subjects will be enrolled in cohorts at different dose levels in order to determine the maximum tolerated dose of cabozantinib. Initially, subjects enrolled will receive the capsule formulation; other subjects will receive the tablet formulation.
Drug: cabozantinib capsules
cabozantinib capsules administered as 25-mg and 100-mg strengths once-daily until disease progression
Other Name: XL184

Drug: cabozantinib tablets
cabozantinib tablets administered as 20-mg and 60-mg strengths once-daily until disease progression
Other Name: XL184

Primary Outcome Measures :
  1. Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose [ Time Frame: Assessed in the clinic on Days 1 through 29 ]
    To establish the MTD and recommended Phase 2 dose (or dose range as appropriate) of XL184 when administered orally on a once daily schedule in subjects with advanced or metastatic solid tumors.

Secondary Outcome Measures :
  1. Safety and tolerability of XL184 [ Time Frame: From study start to October 2014 ]
    Safety and tolerability of multiple doses of XL184 administered orally on a daily basis. Assessed from informed consent until at least 30 days after discontinuation.

  2. Plasma Pharmacokinetics [ Time Frame: Assessed in the clinic from Day 1 through Day 29 ]
    Assess plasma pharmacokinetics of daily oral administration of XL184 from Treatment Day 1 to Day 29.

  3. Tumor response (preliminary anti-tumor activity) [ Time Frame: Study start to October 2014 ]
    Assess tumor response after repeated administration of XL184 from screening until discontinuation. Assessed as best overall response by cohort by radiological response defined by RECIST criteria.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   20 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Select Inclusion Criteria:

  • Subjects with advanced or metastatic solid tumors for whom the standard of care is ineffective or inappropriate.
  • NSCLC expansion cohort subjects must have confirmed NSCLC (Stage IIIb or IV) and documented activating mutations.
  • At least 4 weeks must have elapsed from the last anti-cancer therapy. At least 6 weeks for nitrosoureas, mitomycin C and liposomal doxorubicin.
  • Have adequate bone marrow function, adequate liver function, and adequate renal function.
  • Sexually active subjects (men and women of child-bearing potential (WOCBP)) must agree to use medically accepted barrier methods of contraception (eg, male or female condom) during the course of the study and for 4 months after the last dose of study drug(s), even if oral contraceptives are also used. All subjects of reproductive potential must agree to use both a barrier method and a second method of birth control. Women of childbearing potential (WOCBP) must have a negative pregnancy test at screening.

Select Exclusion Criteria:

  • Symptomatic central nervous system (CNS) metastasis, or active CNS metastasis requiring medication.
  • WOCBP who are unwilling or unable to use an acceptable method of contraception to avoid pregnancy for the entire study period and for 4 months after the last dose of investigational product.
  • Women who are pregnant or breastfeeding.
  • Sexually active fertile men not using effective birth control for the entire study period and for 4 months after the last dose of investigational product if their partners are WOCBP.
  • Subjects who have uncontrolled intercurrent illness including, but not limited to, infection requiring systemic therapy, symptomatic congestive heart failure, uncontrolled hypertension, uncontrolled angina pectoris, uncontrolled peptic ulcer, cardiac arrhythmia requiring medication.
  • Subjects who are HIV antibody positive, HBs antigen positive, and/or HCV antibody positive.
  • Subjects with body cavity fluid retention which requires drainage.
  • Subjects with any major surgery within 8 weeks prior to study enrollment.
  • Subjects with major unhealed wounds or fracture.
  • Subjects with a history or concurrent diagnosis of gastrointestinal perforation.
  • Subjects with evidence of bleeding tendency or coagulopathy.
  • Subjects with a history of thromboembolism.
  • Subjects with a history of or concurrent pancreatitis.
  • Exposure to any investigational drug within 30 days of enrollment.
  • Subjects receiving radiation therapy or treatment with radionuclides within 6 to 2 weeks before first dose of XL184.
  • NSCLC expansion cohorts: subjects must not be diagnosed with another malignancy within 2 years before first dose of XL184.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01553656

Layout table for location information
The Cancer Institute Hospital of the Japanese Foundation for Cancer Research (JFCR)
Ariake, Koto, Japan, 135-8550
National Cancer Center Hospital
Chuo-ku, Tokyo, Japan, 104-0045
Sponsors and Collaborators

Layout table for additonal information
Responsible Party: Exelixis Identifier: NCT01553656     History of Changes
Other Study ID Numbers: XL184-014
First Posted: March 14, 2012    Key Record Dates
Last Update Posted: August 20, 2015
Last Verified: August 2015
Keywords provided by Exelixis:
Advanced cancer